

## **Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019**

*Company will highlight CorPath GRX capabilities in complex vascular procedures*

**WALTHAM, Mass., May 20, 2019** -- [Corindus Vascular Robotics, Inc.](#) (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight recent milestones in technology development, including the latest CE marked technIQ™ Smart Procedural Automation, automated movements aimed at improving navigation, lesion crossing, and delivery of therapy.

The CorPath System is the world’s only U.S. Food and Drug Administration (FDA) cleared and CE marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures. CorPath GRX received CE mark for neurovascular intervention in April 2019, broadening the application of the system to treat all vascular beds in the 33 countries that accept CE mark.

“As healthcare providers around the world continue to augment their services with robotics, we are excited to showcase our latest advancements of the CorPath GRX System at EuroPCR,” said Mark Toland, President and Chief Executive Officer of Corindus. “We truly value the opportunity to collaborate and engage with global, influential industry leaders within the interventional community and we’re honored to take part in EuroPCR for the first time.”

Jean Fajadet, M.D., Interventional Cardiologist at Clinique Pasteur in Toulouse, France, PCR Vice-Chairman, and Course Director of EuroPCR, oversaw the installation of CorPath GRX at Clinique Pasteur earlier this year. The installation cemented the facility as the first site in all of Europe to adopt the latest vascular robotic technology.

“Partnering with Corindus has allowed us to lead the movement of vascular robotics in Europe,” said Jean Fajadet, M.D., Interventional Cardiologist at Clinique Pasteur. “I am impressed with the capabilities of CorPath GRX. The system’s ability to control the guiding catheter, the guidewire, and the rapid exchange catheter (balloon or stent) is critical to performing complex procedures. Furthermore, our procedure rooms are equipped almost entirely with remote capabilities. From imaging to procedural control, our physicians have access to essentially everything they need from the control room.”

EuroPCR, which is the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, will celebrate its 30<sup>th</sup> anniversary and will host more than 11,000 participants from across the globe. For attendees interested in an exclusive opportunity to gain firsthand experience with the latest smart procedural automation technology available on the CorPath GRX System, register [here](#) and visit Corindus at booth M49 through Friday, May 24, 2019.

### **About Corindus Vascular Robotics, Inc.**

Corindus Vascular Robotics is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

### **Forward Looking Statements**

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied

by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control.

Examples of such statements include statements regarding or such as:

- That Corindus will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019;
- Clinique Pastuer leads the movement of vascular robotics in Europe; and
- The participants expected at the European Association of Percutaneous Cardiovascular Interventions.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telesteenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries, including for stroke and other neurovascular interventions; the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at <http://www.corindus.com>.

###

**For more information, contact:**

**Corindus:**

Media Contact:

Matter for Corindus

Jessica Wolter

T: 978-518-4536

[corindus@matternow.com](mailto:corindus@matternow.com)

[www.matternow.com](http://www.matternow.com)

Investor Contact:

Lisa Wilson

In-Site Communications, Inc.

T: 917-543-9932

[ir@corindus.com](mailto:ir@corindus.com)